Development of new adsorbent for selective removal of halogenated anesthetics

参与该项目的多伦多Blue-Zone Technologies公司开发了一种基于专有粒状吸附剂Deltazite®的工艺，用于选择性去除和回收来自医院手术室的低浓度卤化麻醉剂。在手术过程中，只有少量的给药麻醉剂，即少于5%被患者代谢。剩下的95%要么逃逸，要么通过医院的通风系统直接排放到大气中。这些蒸汽被认为是具有侵略性的温室气体，其全球变暖潜能值（GWP）比二氧化碳高出3766倍，并有20年的影响。由于这些麻醉药是有价值的商品（每升成本高达1200美元），Deltasorb®吸附剂与捕获的麻醉药，通过热解吸再生，然后将液化吸附成卤化冷凝物。液化冷凝水是所有三种麻醉剂的混合物，用作下一个过程的原料，例如Blue-Zone专有的分馏过程，其中每个成分被分离，分离和纯化，以达到或超过USP麻醉药物医学标准。

The company involved in this project, Blue-Zone Technologies from Toronto, has developed a process based on proprietary granulated adsorbent Deltazite® for selective removal and recovery of low concentration halogenated anesthetics coming from hospital operating rooms. During operation only a small amount of the administered anesthetic, i.e., less than 5% is metabolized by the patient. The remaining 95% either escapes or is vented through hospital ventilation systems unabated directly into the atmosphere. These vapors are considered aggressive greenhouse gases with the Global Warming Potential (GWP) up to 3,766 times higher than for the CO2 and have a 20 year impact. Since these anesthetics are valuable commodities (costing up to $1,200 per liter) the Deltasorb® adsorbent, with captured anesthetics, is regenerated by thermal desorption and then adsorbates liquefied into halogenated condensate. The liquefied condensate is a mix of all three anesthetics and is used as a feedstock for the next process, e.g., Blue-Zone proprietary fractional distillation process, where each component is isolated, separated and purified to meet or exceed the USP anesthetic drug medical standards.